(Q41348477)

29 September 2017

1 reference

title

Olanzapine. A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses (English)

1 reference

29 September 2017

0 references

B Fulton

1

1 reference

PubMed ID

9028746

29 September 2017

K L Goa

series ordinal

2

1 reference

29 September 2017

1 February 1997

1 reference

29 September 2017

1 reference

29 September 2017

53

1 reference

29 September 2017

2

1 reference

29 September 2017

281-298

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199753020-00007

29 September 2017

0 references

cites work

Olanzapine: a new typical antipsychotic drug

1 reference

12 December 2020

Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding

1 reference

12 December 2020

Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine.

1 reference

12 December 2020

Effects of olanzapine on regional C-Fos expression in rat forebrain.

1 reference

12 December 2020

Dopamine receptor pharmacology

1 reference

12 December 2020

Comparison of the new atypical antipsychotics olanzapine and ICI 204,636 with clozapine on behavioural responses to the selective "D1-like" dopamine receptor agonist A 68930 and selective "D2-like" agonist RU 24213

1 reference

12 December 2020

D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs

1 reference

12 December 2020

Distribution of putative D4 dopamine receptors in postmortem striatum from patients with schizophrenia.

1 reference

12 December 2020

Neuroleptic treatment of negative symptoms in schizophrenic patients. Efficacy problems and methodological difficulties

1 reference

12 December 2020

A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects

1 reference

12 December 2020

The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent

1 reference

12 December 2020

Differential effect of antipsychotics on place navigation of rats in the Morris water maze. A comparative study between novel and reference antipsychotics.

1 reference

12 December 2020

First clinical experience with olanzapine (LY 170053): results of an open-label safety and dose-ranging study in patients with schizophrenia.

1 reference

12 December 2020

Measuring the costs of schizophrenia. Implications for the post-institutional era in the US.

1 reference

12 December 2020

A rating scale for drug-induced akathisia

1 reference

12 December 2020

Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability

1 reference

12 December 2020

Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) study.

1 reference

12 December 2020

Antipsychotic agents antagonize non-competitive N-methyl-D-aspartate antagonist-induced behaviors

1 reference

12 December 2020

Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial

1 reference

12 December 2020

Dopamine D4 receptors elevated in schizophrenia

1 reference

12 December 2020

Olanzapine, a novel atypical antipsychotic, reverses d-amphetamine-induced inhibition of midbrain dopamine cells.

1 reference

12 December 2020

1 reference

12 December 2020

Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine (LY170053), an antipsychotic drug candidate

1 reference

12 December 2020

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

1 reference

12 December 2020

Radioreceptor binding profile of the atypical antipsychotic olanzapine.

1 reference

12 December 2020

Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha 1-adrenergic and muscarinic receptors in vivo in rats.

1 reference

12 December 2020

Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine

1 reference

12 December 2020

Effects of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule

1 reference

12 December 2020

New drugs for the treatment of schizophrenic patients

1 reference

12 December 2020

The olfactory tubercle as a site of action of neuroleptics with an atypical profile in the paw test: effect of risperidone, prothipendyl, ORG 5222, sertindole and olanzapine

1 reference

12 December 2020

Negative symptoms in schizophrenia. Definition and reliability

1 reference

12 December 2020

Olanzapine, an atypical antipsychotic, increases rates of punished responding in pigeons.

1 reference

12 December 2020

In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A

1 reference

12 December 2020

Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values

1 reference

12 December 2020

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

1 reference

12 December 2020

Differential effects of repeated administration of novel antipsychotic drugs on the activity of midbrain dopamine neurons in the rat

1 reference

12 December 2020

Pre-clinical pharmacology of atypical antipsychotic drugs: a selective review

1 reference

12 December 2020

Anchoring the BPRS: an aid to improved reliability

1 reference

12 December 2020

A rating scale for extrapyramidal side effects

1 reference

12 December 2020

Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors

1 reference

12 December 2020

Mechanisms of action of atypical antipsychotic drugs: a critical analysis

1 reference

12 December 2020

Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons.

1 reference

12 December 2020

10.2165/00003495-199753020-00007

Identifiers

DOI

1 reference

PubMed ID

9028746

Dimensions Publication ID

29 September 2017

0 references

1 reference

PubMed ID

9028746